Jose Luis Gorriz
University of Valencia, Spain
Title: Atrial fibrillation & chronic kidney disease: focus on rivaroxaban
Biography
Biography: Jose Luis Gorriz
Abstract
Abstract: Renal insufficiency increases the risk of stroke and bleeding in atrial fibrillation patients. Although vitamin K antagonists reduce the risk of stroke in patients with moderate renal dysfunction, this observation is less clear in patients with renal impairment. Moreover, the risk of bleeding with vitamin K antagonists increases as renal function worsens. Maintaining international normalized ratio values within therapeutic targets is more difficult in patients with renal dysfunction, and those agents may cause warfarin-related nephropathy and vascular calcification. Rivaroxaban is the only nonvitamin K oral anticoagulant with a dose specifically tested in patients with moderate renal insufficiency. Rivaroxaban is effective for the prevention of stroke in atrial fibrillation patients with moderate renal dysfunction, with a lower risk of intracranial and fatal bleeding. Key words: Atrial fibrillation , chronic kidney disease , new oral anticoagulant, nonvitamin K oral anticoagulant , renal function , renal insufficiency , rivaroxaban, vitamin K antagonist.